179 related articles for article (PubMed ID: 29435174)
1. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
Oncotarget; 2018 Jan; 9(4):5216-5232. PubMed ID: 29435174
[TBL] [Abstract][Full Text] [Related]
2. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
[TBL] [Abstract][Full Text] [Related]
4. CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients.
Wang D; Zhou Y; Hua L; Li J; Zhu N; Liu Y
Int J Gen Med; 2022; 15():2233-2245. PubMed ID: 35250301
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
6. Promising Anticancer Activity of Multitarget Cyclin Dependent Kinase Inhibitors against Human Colorectal Carcinoma Cells.
Manohar SM; Joshi KS
Curr Mol Pharmacol; 2022; 15(7):1024-1033. PubMed ID: 35068399
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cyclin-dependent Kinase (CDK) Decreased Survival of NB4 Leukemic Cells: Proposing a p53-Independent Sensitivity of Leukemic Cells to Multi-CDKs Inhibitor AT7519.
Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Shanaki M; Yousefi AM; Anjam Najmedini A; Bashash D
Iran J Pharm Res; 2020; 19(3):144-155. PubMed ID: 33680018
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
Qu H; Yin H; Yan S; Tao M; Xie Y; Chen W
Oncol Rep; 2016 May; 35(5):2927-35. PubMed ID: 26936485
[TBL] [Abstract][Full Text] [Related]
9. Molecular pharmacology of multitarget cyclin-dependent kinase inhibitors in human colorectal carcinoma cells.
Manohar SM; Joshi KS
Expert Opin Ther Targets; 2023 Mar; 27(3):251-261. PubMed ID: 37015886
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
11. CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis.
Zhuang K; Zhang J; Xiong M; Wang X; Luo X; Han L; Meng Y; Zhang Y; Liao W; Liu S
Cell Death Dis; 2016 Oct; 7(10):e2415. PubMed ID: 27735944
[TBL] [Abstract][Full Text] [Related]
12. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.
Niu P; Tao Y; Meng Q; Huang Y; Li S; Ding K; Ma D; Ye Z; Fan M
Bioorg Med Chem; 2024 Apr; 104():117711. PubMed ID: 38583237
[TBL] [Abstract][Full Text] [Related]
15. TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma.
Amin N; Wang H; Song Q; Bhaskar M; Yadav SP; Gilbert MR; Pant H; Tabouret E; Zhuang Z
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511490
[TBL] [Abstract][Full Text] [Related]
16. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
17. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation.
Sharma P; Sharma M; Amin ND; Albers RW; Pant HC
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11156-60. PubMed ID: 10500146
[TBL] [Abstract][Full Text] [Related]
19. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
20. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy.
Dai L; Liu Y; Liu J; Wen X; Xu Z; Wang Z; Sun H; Tang S; Maguire AR; Quan J; Zhang H; Ye T
Cancer Lett; 2013 Jun; 333(1):103-12. PubMed ID: 23354589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
